Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort)

Abstract

The main aim of the Leucémies de l'Enfant et l'Adolescent (LEA) project (Childhood and Adolescent Leukaemia) is to study the determinants (medical, socioeconomic, behavioural and environmental) of medium- and long-term outcomes of patients treated for childhood acute leukaemia (AL). The LEA study began in 2004 and is based on a French multicentric prospective cohort. Included are children treated for AL since January 1980 (incident and prevalent cases), surviving at month 24 for myeloblastic AL and lymphoblastic AL grafted in first complete remission or at month 48 for lymphoblastic AL not grafted in first complete remission. Information is collected during specific medical visits and notably includes the following data: socioeconomic data, AL history, physical late effects (such as fertility, cardiac function and metabolic syndrome) and quality of life. Data are collected every 2 years until the patient is 20 years old and has had a 10-year follow-up duration from diagnosis or last relapse. Thereafter, assessments are planned every 4 years. In active centres in 2013, eligible patients number more than 3000. The cohort has already included 2385 survivors, with rate of exhaustiveness of almost 80%. Data access can be requested from principal coordinators and must be approved by the steering committee.

Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study

“…is a long-term follow-up program involving all childhood AL survivors treated in the French participating centers since 1980. As detailed elsewhere, 21 participants are summoned to the followup clinic at predefined dates, starting one year after completion of chemotherapy. These visits are repeated every two years until the age of 20 and at least 10 years of complete remission, and every four years thereafter.…”

Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study

“…Further details of the program have been described elsewhere. 20,21 The eligibility criteria for this study were the following: (i) provision of written informed consent to participation in the L.E.A. program between 2004 and 2012, and (ii) having received central nervous system irradiation and/or undergone hematopoietic stem cell transplantation with a myeloablative conditioning regimen as part of the treatment.…”

Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study

“…Details of the entire program have been previously described. 15,16 Since 2007, the assessment of MS was systematically proposed to all adults with a new LEA health status evaluation. The eligibility criteria were the following: (1) the provision of written informed consent for study participation in the LEA study, (2) age 418 years at the last LEA evaluation, (3) having received an HSCT after a myeloablative conditioning regimen.…”